Brainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a hold rating to a sell rating in a report released on Tuesday morning.

Brainstorm Cell Therapeutics Price Performance

NASDAQ:BCLI opened at $1.13 on Tuesday. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89. The company has a market cap of $6.01 million, a PE ratio of -0.33 and a beta of 0.40. The firm has a 50-day moving average of $2.59 and a 200-day moving average of $4.75.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). During the same period in the previous year, the company earned ($4.05) earnings per share. On average, equities research analysts expect that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.